Read all about what we’ve been up to in our latest news and recent publications.
Effective comparison of single-cell embedding visualizations.
August 10, 2023
At ISMB 2023, Ozette’s Trevor Manz lead a lively panel on effective comparison of single-cell embedding visualizations. To better understand the approach, challenges, and conclusions, learn more by downloading the event poster here.
Automated gating and antigen-specific T cells subset discovery using FAUST and COMPASS on ICS data.
August 8, 2023
At ISMB 2022, Ozette Computational Biologist Malisa Smith, and Ozette Co-Founder Evan Greene, PhD VP of Quantitative Methods discussed automated gating and antigen-specific T cells subset discovery using FAUST and COMPASS on ICS data as well as how they reanalyzed a published Intracellular Cytokine Staining (ICS) dataset. Download the poster to learn more about their presentation.
Discovering data transformations for effective visualization of single-cell embeddings.
August 3, 2023
At ISMB 2022, Ozette’s Fritz Lekschas, PhD, Head of Visualization Research lead a fascinating discussion about data transformations for effective visualization of single-cell embeddings. If you weren’t able to attend, take a look at this beautiful and though provoking work.
From assay to endpoints, see how Ozette’s proprietary processes deliver results.
July 20, 2023
Recently, at CYTO 2023, we showcased how Ozette Endpoints™ and Ozette Discovery™ technologies leverage Artificial Intelligence and Machine Learning to deliver robust computational analysis pipelines and allow for rapid insights into complex high-dimensional data. View process details, methods, and case study examples in our detailed conference poster.
Vaccination induces HIV broadly neutralizing antibody precursors in humans.
June 17, 2023
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial...
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
May 20, 2023
The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need to be matured, through additional heterologous immunizations, into B cells that are able to produce broadly neutralizing antibodies. CD4 T cell help will be critical for the development of such high-affinity neutralizing antibody responses. Thus, we assessed the induction and epitope specificities of the vaccine-specific T cells...